You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 17, 2024

Investigational Drug Information for Obicetrapib


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Obicetrapib?

Obicetrapib is an investigational drug.

There have been 8 clinical trials for Obicetrapib. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2022.

The most common disease conditions in clinical trials are Dyslipidemias, Hypercholesterolemia, and Hyperlipoproteinemia Type II. The leading clinical trial sponsors are NewAmsterdam Pharma and [disabled in preview].

There are three US patents protecting this investigational drug and eighty-nine international patents.

Recent Clinical Trials for Obicetrapib
TitleSponsorPhase
Randomized Study in Patients With HeFH to Evaluate Obicetrapib on Top of Maximum Tolerated Lipid-Modifying TherapiesNewAmsterdam PharmaPhase 3
A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.NewAmsterdam PharmaPhase 2
Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS TherapyNewAmsterdam PharmaPhase 2

See all Obicetrapib clinical trials

Clinical Trial Summary for Obicetrapib

Top disease conditions for Obicetrapib
Top clinical trial sponsors for Obicetrapib

See all Obicetrapib clinical trials

US Patents for Obicetrapib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Obicetrapib ⤷  Try a Trial Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives DEZIMA PHARMA B.V. (Naarden, NL) ⤷  Try a Trial
Obicetrapib ⤷  Try a Trial Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors DEZIMA PHARMA B.V. (NL) ⤷  Try a Trial
Obicetrapib ⤷  Try a Trial Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases DEZIMA PHARMA BV (NL) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Obicetrapib

Drugname Country Document Number Estimated Expiration Related US Patent
Obicetrapib Argentina AR101509 2034-08-12 ⤷  Try a Trial
Obicetrapib Australia AU2015302407 2034-08-12 ⤷  Try a Trial
Obicetrapib Brazil BR112017002873 2034-08-12 ⤷  Try a Trial
Obicetrapib Canada CA2958040 2034-08-12 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.